Rezolute Stock Rises Following Upgrade by Citizens JMP Securities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: seekingalpha
- Stock Upgrade Impact: Rezolute (RZLT) traded higher for the third consecutive session on Wednesday after Citizens JMP Securities upgraded its rating from Market Perform to Market Outperform, reflecting a positive market sentiment towards the company's future prospects.
- Clinical Trial Progress: The company's interim data from the upLIFT Phase 3 study for its lead asset, ersodetug, in tumor hyperinsulinism, released on Tuesday, triggered nearly an 11% stock price increase, showcasing the drug's potential in the rare disease space.
- FDA Approval Outlook: Analyst Jason Butler noted that the approval pathway for ersodetug in tumor hyperinsulinism could be distinct from the setbacks faced last year in congenital hyperinsulinism, providing confidence for FDA approval with a target price set at $11.
- Positive Market Reaction: The stock's rise due to favorable clinical data and the analyst's optimistic rating indicates that investors are increasingly confident in the company's potential success in treating rare diseases, likely attracting more investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RZLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RZLT
Wall Street analysts forecast RZLT stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 4.000
Low
2.00
Averages
6.29
High
20.00
Current: 4.000
Low
2.00
Averages
6.29
High
20.00
About RZLT
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rezolute Stock Rises Following Upgrade by Citizens JMP Securities
- Stock Upgrade Impact: Rezolute (RZLT) traded higher for the third consecutive session on Wednesday after Citizens JMP Securities upgraded its rating from Market Perform to Market Outperform, reflecting a positive market sentiment towards the company's future prospects.
- Clinical Trial Progress: The company's interim data from the upLIFT Phase 3 study for its lead asset, ersodetug, in tumor hyperinsulinism, released on Tuesday, triggered nearly an 11% stock price increase, showcasing the drug's potential in the rare disease space.
- FDA Approval Outlook: Analyst Jason Butler noted that the approval pathway for ersodetug in tumor hyperinsulinism could be distinct from the setbacks faced last year in congenital hyperinsulinism, providing confidence for FDA approval with a target price set at $11.
- Positive Market Reaction: The stock's rise due to favorable clinical data and the analyst's optimistic rating indicates that investors are increasingly confident in the company's potential success in treating rare diseases, likely attracting more investor interest.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
Rezolute Updates Late-Stage Trial Progress for Ersodetug
- Participant Progress: Rezolute has enrolled 8 patients in its upLIFT Phase 3 study, with 6 achieving the necessary level to measure the trial's primary endpoint, indicating treatment efficacy and laying a foundation for future market potential.
- Significant Treatment Effects: All 6 participants discontinued intravenous glucose requirements after therapy, demonstrating positive outcomes in addressing hypoglycemia, which may attract increased investor interest.
- Good Safety Profile: The company reported no safety concerns during the pivotal and extension phases of the study, enhancing confidence in the therapy and potentially accelerating subsequent regulatory approval processes.
- Data Release Timeline: The upLIFT trial has reached 50% of its enrollment target, with topline data expected to be reported in H2 2026, further advancing the company's strategic positioning in the rare disease treatment space.
See More
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
Rezolute Presents New Data on Ersodetug Study Outcomes
- Glycemic Control Improvement: In the sunRIZE study, the ersodetug treatment group showed clinically relevant reductions of over 50% in average daily time in hypoglycemia, while the placebo group did not achieve statistical significance, indicating the drug's potential in improving glycemic control.
- Strong Treatment Continuity: During the open-label extension phase, all 59 participants opted to continue receiving ersodetug, with 57 attending regular study visits, demonstrating good tolerability and sustained efficacy of the drug in long-term use.
- Reduction in Background Therapy: The use of ersodetug has led to a significant decrease in standard treatments (e.g., diazoxide, somatostatin analogs) for many patients, showcasing the drug's effectiveness as a monotherapy.
- Positive FDA Interaction: Rezolute's meeting with the FDA acknowledged challenges with the study's primary endpoint and requested broader data submission for further evaluation, reflecting the company's confidence and efforts toward obtaining approval.
See More
Rezolute's Positive FDA Meeting Outcomes for sunRIZE Program
- FDA Meeting Outcomes: Rezolute's March 17, 2026 meeting with the FDA yielded positive feedback, as the agency did not outright dismiss the sunRIZE study despite it not meeting its primary endpoint, indicating interest in further review.
- Clinical Data Insights: The company presented summary results from the sunRIZE study, highlighting that behavioral factors may have confounded the primary endpoint's statistical significance, while significant improvements in time in hypoglycemia were observed via CGM monitoring, suggesting potential drug efficacy.
- Next Steps Encouraged: The FDA urged Rezolute to submit study reports and analysis datasets for independent evaluation, which could pave the way for a marketing application for sunRIZE, reflecting the agency's cautious approach to new therapies.
- Patient Needs Emphasized: During the meeting, the FDA and Rezolute discussed the profound impact of congenital hyperinsulinism on patients, underscoring the necessity for new treatment options and reflecting a shared commitment to improving patient care.
See More
Rezolute Stock Rises Following Upgrade by Citizens JMP Securities
- Stock Upgrade Impact: Rezolute (RZLT) traded higher for the third consecutive session on Wednesday after Citizens JMP Securities upgraded its rating from Market Perform to Market Outperform, reflecting a positive market sentiment towards the company's future prospects.
- Clinical Trial Progress: The company's interim data from the upLIFT Phase 3 study for its lead asset, ersodetug, in tumor hyperinsulinism, released on Tuesday, triggered nearly an 11% stock price increase, showcasing the drug's potential in the rare disease space.
- FDA Approval Outlook: Analyst Jason Butler noted that the approval pathway for ersodetug in tumor hyperinsulinism could be distinct from the setbacks faced last year in congenital hyperinsulinism, providing confidence for FDA approval with a target price set at $11.
- Positive Market Reaction: The stock's rise due to favorable clinical data and the analyst's optimistic rating indicates that investors are increasingly confident in the company's potential success in treating rare diseases, likely attracting more investor interest.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
Rezolute Updates Late-Stage Trial Progress for Ersodetug
- Participant Progress: Rezolute has enrolled 8 patients in its upLIFT Phase 3 study, with 6 achieving the necessary level to measure the trial's primary endpoint, indicating treatment efficacy and laying a foundation for future market potential.
- Significant Treatment Effects: All 6 participants discontinued intravenous glucose requirements after therapy, demonstrating positive outcomes in addressing hypoglycemia, which may attract increased investor interest.
- Good Safety Profile: The company reported no safety concerns during the pivotal and extension phases of the study, enhancing confidence in the therapy and potentially accelerating subsequent regulatory approval processes.
- Data Release Timeline: The upLIFT trial has reached 50% of its enrollment target, with topline data expected to be reported in H2 2026, further advancing the company's strategic positioning in the rare disease treatment space.
See More
Rezolute Reports Q3 Earnings Beat Expectations
- Earnings Beat: Rezolute reported a Q3 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Position: As of March 31, 2026, the company had $120.3 million in cash, cash equivalents, and marketable securities, down from $167.9 million as of June 30, 2025, reflecting pressure on the company's financial management.
- FDA Meeting Feedback: Despite receiving positive feedback from the FDA meeting, the market remains cautious about the prospects of its lead asset, leading analysts to maintain a
See More
Rezolute Presents New Data on Ersodetug Study Outcomes
- Glycemic Control Improvement: In the sunRIZE study, the ersodetug treatment group showed clinically relevant reductions of over 50% in average daily time in hypoglycemia, while the placebo group did not achieve statistical significance, indicating the drug's potential in improving glycemic control.
- Strong Treatment Continuity: During the open-label extension phase, all 59 participants opted to continue receiving ersodetug, with 57 attending regular study visits, demonstrating good tolerability and sustained efficacy of the drug in long-term use.
- Reduction in Background Therapy: The use of ersodetug has led to a significant decrease in standard treatments (e.g., diazoxide, somatostatin analogs) for many patients, showcasing the drug's effectiveness as a monotherapy.
- Positive FDA Interaction: Rezolute's meeting with the FDA acknowledged challenges with the study's primary endpoint and requested broader data submission for further evaluation, reflecting the company's confidence and efforts toward obtaining approval.
See More
Rezolute's Positive FDA Meeting Outcomes for sunRIZE Program
- FDA Meeting Outcomes: Rezolute's March 17, 2026 meeting with the FDA yielded positive feedback, as the agency did not outright dismiss the sunRIZE study despite it not meeting its primary endpoint, indicating interest in further review.
- Clinical Data Insights: The company presented summary results from the sunRIZE study, highlighting that behavioral factors may have confounded the primary endpoint's statistical significance, while significant improvements in time in hypoglycemia were observed via CGM monitoring, suggesting potential drug efficacy.
- Next Steps Encouraged: The FDA urged Rezolute to submit study reports and analysis datasets for independent evaluation, which could pave the way for a marketing application for sunRIZE, reflecting the agency's cautious approach to new therapies.
- Patient Needs Emphasized: During the meeting, the FDA and Rezolute discussed the profound impact of congenital hyperinsulinism on patients, underscoring the necessity for new treatment options and reflecting a shared commitment to improving patient care.
See More
